← Back to Search

FET-PET/MRI for Brain Tumors (FETSMaRT Trial)

N/A
Waitlist Available
Led By Amit Singnurkar, MD, MBA
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
No prior radiation or systemic treatment for high grade glioma
High grade brain glioma (Grade 3 and 4)
Must not have
Creatinine clearance < 30mL/min
Inability to lie still for 40 minutes
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to develop a new imaging technique using a tracer called FET for brain gliomas in Ontario. Gliomas are a type of brain cancer, with the most aggressive form being gliob

Who is the study for?
This trial is for patients with high-grade brain gliomas, specifically those who are likely to benefit from precise therapy planning. It's not clear who can't participate since the exclusion criteria aren't provided.
What is being tested?
The study is testing if a PET imaging agent called 0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) can better identify tumor boundaries in the brain compared to standard MRI, which could improve treatment planning and monitoring.
What are the potential side effects?
Potential side effects of FET-PET imaging are not detailed here, but generally PET scans have minimal side effects, possibly including discomfort from lying still or reactions at the injection site.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I haven't had radiation or systemic treatment for my high grade brain tumor.
Select...
My brain tumor is high grade (Grade 3 or 4).
Select...
I am 18 years old or older.
Select...
I can undergo a PET/MRI scan with contrast.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My kidney function is severely reduced.
Select...
I cannot stay still for 40 minutes.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Observe recurrence/evaluate diagnostic performance of PET-FET/MRI vs MRI alone
Secondary study objectives
Analysis of PET Data
Evaluate recurrence
Evaluate tumor volume changes

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: High Grade GliomaExperimental Treatment1 Intervention
0-(2-18F-Fluoroethyl)-L-Tyrosine (FET) PET/MRI for planning of radiation therapy of post-operative grade III/IV glioma patients

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
681 Previous Clinical Trials
1,565,728 Total Patients Enrolled
Amit Singnurkar, MD, MBAPrincipal InvestigatorSunnybrook Healthcare Centre
~0 spots leftby Jan 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top